Table 1.

Main characteristics of all studies included in the meta-analysis.

Study	Origin of population	Tumor type	Age (years, n)	Gender (M/F)	Sample number	Stage	Follow-up (months)	Source of miRNA	miR-375 assay	Cut-off definition	Multivariate analysis	Survival analysis	HR
Yu et al. 2014a [16]	China	NSCLC	<60, 96; ≥60, 68	86/78	164	I–IV	Median 24 (rang: 0–56)	Blood	qRT-PCR	Median	Yes	OS	Report
Yu et al. 2014b [16]	China	NSCLC	NR	NR	53	I–IV	Median 24 (rang: 0–56)	Blood	qRT-PCR	Median	Yes	OS	Report
Wu et al. 2014 [17]	China	ESCC	Mean 61.4 (33–81)	115/79	194	I–IV	Median 31.3	Blood	qRT-PCR	Mean	Yes	OS	Report
Li et al. 2012 [18]	China	NSCLC	Median 61 (37–75)	70/26	96	I–III	Median 30 (rang: 8–69)	Tissue	qRT-PCR	Mean	Yes	OS	Report
Chang et al. 2012 [19]	China	Glioma	Median 42 (12–71)	76/52	128	I–IV	60	Tissue	qRT-PCR	Median	Yes	OS	Report
Madhavan et al. 2012 [20]	Germany	Breast	NR	0/164	164	IV	NR	Blood	qRT-PCR	Lower quartile	No	OS, PFS	DE
Zhang et al. 2011 [26]	China	Gastric	30–83	43/22	65	I–IV	Over 60	Tissue	qRT-PCR	2-fold	No	OS	DE
Harris et al. 2012 [27]	USA	HNSCC	62.2 ± 11.9	85/38	123	I–IV	NR	Tissue	qRT-PCR	Lower quartile	Yes	OS	Report
Ma et al. 2013 [21]	China	PDAC	NR	44/34	78	I–IV	NR	Tissue	qRT-PCR	Mean	Yes	OS	Report
Nguyen et al. 2010 [22]	USA, Canada	EADC	32–80	35/23	58	I–IV	Median 72	Tissue	qRT-PCR	Median	Yes	OS	Report
Kong et al. 2012 [23]	China	ESCC	Mean 66	43/17	60	I–IV	Over 60	Tissue	qRT-PCR	Normal	No	OS, DFS	DE
Li et al. 2013 [24]	China	ESCC	≤60, 105; >60, 144	136/113	249	I–IV	Over 60	Tissue	MISH	Normal	No	OS	DE
Komatsu et al. 2012 [25]	Japan	ESCC	Median 65	44/6	50	0–IV	36	Blood	qRT-PCR	Median	No	OS	DE
Mathe et al. 2009c [12]	USA, Canada	EADC	NR	NR	63	I–IV	Median 60	Tissue	qRT-PCR	Median	No	OS	DE
Mathe et al. 2009d [12]	USA, Canada	EADC	NR	NR	37	I–IV	Median 60	Tissue	qRT-PCR	Median	No	OS	DE
Mathe et al. 2009e [12]	USA, Japan	ESCC	<62, 28; ≥62, 42	52/18	70	I–IV	Median 60	Tissue	qRT-PCR	Median	No	OS	DE

NSCLC: non-small cell lung cancer; ESCC: esophageal squamous cell carcinoma; HNSCC: head and neck squamous cell carcinoma; EADC: esophageal adenocarcinoma; qRT-PCR: quantitative real-time PCR; MISH: miRNA in situ hybridization; OS: overall survival; DFS: disease-free survival; PFS: progression-free survival; HR: hazard ratio; DE: data extrapolated; NR: not reported.

^aStudy by Yu et al. [16] that evaluated the association between miR-375 expression and OS in a discovery cohort of 164 NSCLC patients.

^bStudy by Yu et al. [16] that evaluated the association between miR-375 expression and OS in a validation cohort of 53 NSCLC patients.

^cStudy by Mathe et al. [12] that evaluated the association between miR-375 expression and OS in a validation cohort of 63 EADC patients with Barrett's.

^dStudy by Mathe et al. [12] that evaluated the association between miR-375 expression and OS in a validation cohort of 37 EADC patients without Barrett's.

^eStudy by Mathe et al. [12] that evaluated the association between miR-375 expression and OS in a validation cohort of 70 ESCC patients.